Staphylococcus Aureus Network Adaptive Platform Trial

Status Recruiting

Clinical Trial Summary

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Clinical Trial Description

Infection of the bloodstream with the bacterium Staphylococcus aureus (Staphylococcus aureus bacteraemia, SAB) is a serious infection that results in 15-30% of affected patients dying within three months of acquiring the infection. Treatment of this infection requires patients to be hospitalised, treated with prolonged antibiotics through an intravenous line, and carefully examined for the occurrence of complications associated with this condition. At present, there are many treatment options in current use, with no clear agreement as to which of these is best. The SNAP trial aims to identify which treatment options for SAB results in the fewest patients dying within the first 90 days after an infection. In contrast to a conventional clinical trial, the SNAP trial will examine multiple different treatment options at once. Patients will be randomly assigned to different concurrent treatment options currently considered acceptable in routine medical care, but as the trial progresses, more patients will be assigned to treatments that appear to have better outcomes than those with worse outcomes. The trial will adapt to accumulating trial evidence, on a regular basis, by removing treatment options found to be inferior, incorporating new treatment options, and ensuring that all patients in the trial receive the best treatments once they have been identified. Over time, we hope to determine the best combination of treatment options for patients with SAB. The SNAP Trial infrastructure will also support a number of sub-studies. A list of all active sub-studies can be found on the SNAP website: https://www.snaptrial.com.au/substudies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05137119
Study type	Interventional
Source	University of Melbourne
Contact	Lauren Barina
Phone	+61 (03) 8344 1623
Email	lauren.barina@unimelb.edu.au
Status	Recruiting
Phase	Phase 4
Start date	February 16, 2022
Completion date	December 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05862025` - Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).	N/A
Not yet recruiting	`NCT05361135` - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia	N/A
Recruiting	`NCT00622882` - Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia	N/A
Recruiting	`NCT06168474` - Evaluating Simplified Layered Consent for Clinical Trials	N/A
Completed	`NCT03163446` - Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia	Phase 2
Not yet recruiting	`NCT06336824` - Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia	Phase 3
Completed	`NCT02357966` - A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus	Phase 1/Phase 2
Recruiting	`NCT04886284` - Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia	Phase 2
Terminated	`NCT03089697` - Phase IIa Clinical Study of N-Rephasin® SAL200	Phase 2
Recruiting	`NCT03514446` - Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia	Phase 4
Withdrawn	`NCT03761953` - Oritavancin for Staphylococcus Aureus Infections in Opioid Users	Phase 4
Recruiting	`NCT06249451` - Staphylococcus Aureus Bacteraemia (SAB)-Support-Study	N/A
Recruiting	`NCT02098850` - Staphylococcus Aureus Bacteraemia in Adults	N/A
Completed	`NCT01701219` - Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia	Phase 4
Completed	`NCT03908086` - Bloodstream Infections in Patients With Rheumatoid Arthritis
Terminated	`NCT04160468` - Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase	Phase 3
Completed	`NCT03138733` - Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia	Phase 3
Completed	`NCT02476487` - The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia	N/A
Recruiting	`NCT05184764` - Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia	Phase 1/Phase 2
Completed	`NCT01971762` - Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Staphylococcus Aureus Network Adaptive Platform Trial — SNAP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms